Even though no NIK inhibitor has entered the clinic yet, NIK represents a promising therapeutic target that should be addressed more vigorously, particularly regarding the treatment of multiple myeloma and MALT lymphoma expressing the oncogenic cIAP2-MALT1 fusion protein [188,259]. The gene discussed is MALT1; the disease is plasma cell myeloma.